DOTA-1: Single-Fraction MR-guided Stereotactic Ablative Radiotherapy for Localized Prostate Cancer (DOTA-1)

November 15, 2026 updated by: Ratchapas Romrattaphan, Mahidol University

DOminant-TArgeted Stereotactic Ablative Radiotherapy in Localized Prostate Cancer: Single-fraction Phase I/II Pilot Study (DOTA-1)

This single-center, single-arm phase I/II pilot study evaluates the safety and feasibility of single-fraction stereotactic body radiotherapy (SBRT) with a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) in men with localized prostate cancer.

Ten participants with very low-, low-, or favorable intermediate-risk prostate adenocarcinoma and an MRI-visible DIL (PI-RADS 4-5) will be enrolled. After hydrogel rectal spacer insertion, patients receive MR-guided SBRT on an MR-Linac in one fraction: 20 Gy to the whole prostate, 26 Gy to the DIL, and 15 Gy to the seminal vesicles. The aim is to deliver a brachytherapy-like ablative dose without an invasive procedure.

The primary outcome is acute genitourinary and rectal toxicity (CTCAE v5.0) within 3 months after treatment. Secondary outcomes include late toxicity, patient-reported quality of life (IPSS, IIEF, FACT-P), biochemical failure-free survival (Phoenix definition), local recurrence-free, progression-free, distant metastasis-free and overall survival, correlation of MR-radiomics with clinical outcomes, and cost-effectiveness. Patients will be followed for 5 years.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Bangkok
      • Bangkok Noi, Bangkok, Thailand, 10700
        • Recruiting
        • Siriraj Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  1. Men ≥ 18 years old

  2. Newly diagnosed and histologically confirmed localized prostate adenocarcinoma

  3. Very low-, low-, and favorable intermediate-risk via NCCN risk group classification, defined as;

    • Gleason grade group 1 or 2
    • Clinical stage T1-T2c
    • Initial PSA < 20 ng/ml (Patient can have only one of cT2b-cT2c, Gleason grade group 2 and PSA 10-20 ng/ml)
  4. Visible dominant-intraprostatic lesion (DIL) on multi-parametric MRI defined by PI-RADS classification

  5. ECOG Performance Status 0-2 within 28 days prior to study entry

  6. Patients must be able to provide study-specific informed consent prior to study entry.

Exclusion Criteria:

  1. Direct extraprostatic extension into the adjacent structures
  2. Extraprostatic metastases or malignant nodes
  3. Large prostate volume > 60 cm3 by imaging
  4. Use of Androgen deprivation therapy
  5. Baseline IPSS > 13
  6. MRI-contraindicated patient (eg., MRI-incompatible pacemaker, metal implant)
  7. Patient with hip prosthesis which causes artifact on MR images
  8. Patient with significant predisposing comorbidity (eg. inflammatory bowel disease)
  9. Prior radiotherapy to the region of the pelvis that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
  10. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 2 years (Note that carcinoma in situ of the breast, oral cavity, or cervix are all permissible)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Single-fraction MR-guided SBRT

A single fraction of stereotactic body radiotherapy (SBRT) delivered on a 1.5T MR-Linac with daily MRI guidance, using IMRT with a simultaneous integrated boost. Prescribed doses: 26 Gy to the dominant intraprostatic lesion (DIL; PI-RADS 4-5 lesion on multiparametric MRI), 20 Gy to the whole prostate, and 15 Gy to the seminal vesicles. A hydrogel rectal spacer is inserted before CT/MR simulation. Before simulation and treatment, patients follow a bladder protocol (void, then drink 200-300 mL of water) and empty the rectum. No androgen deprivation therapy is given.

Other Names:
  • Single-fraction SABR with DIL boost
  • DOTA-1 regimen

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Acute toxicity (Genitourinary and Gastrointestinal toxicity)
Time Frame: Up to 3 months after SBRT

Incidence of acute treatment-related toxicity from the date of treatment by radiotherapy up to 3 months after completion of radiotherapy, assessed using CTCAE version 5.0

Up to 3 months after SBRT

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Late toxicity (Genitourinary and Gastrointestinal toxicity)
Time Frame: From 3 months to 5 years after SBRT

Incidence of late (chronic) treatment-related toxicity from 3 months after completion of radiotherapy up to 5 years after completion of radiotherapy, assessed using CTCAE version 5.0

From 3 months to 5 years after SBRT
International Prostate Symptom Score (I-PSS)
Time Frame: Baseline and at each follow-up visit up to 5 years after SBRT

Patient-reported urinary symptoms assessed using the I-PSS. The total score ranges from 0 to 35; higher scores indicate worse urinary symptoms.

Baseline and at each follow-up visit up to 5 years after SBRT
International Index of Erectile Function (IIEF-5) score
Time Frame: Baseline and at each follow-up visit up to 5 years after SBRT

Patient-reported erectile function assessed using the IIEF-5 Score. The total score ranges from 5 to 25; higher scores indicate better erectile function.

Baseline and at each follow-up visit up to 5 years after SBRT
Functional Assessment of Cancer Therapy - Prostate (FACT-P) score
Time Frame: Baseline and at each follow-up visit up to 5 years after SBRT

Health-related quality of life assessed using the FACT-P. The total score ranges from 0 to 156; higher scores indicate better quality of life.

Baseline and at each follow-up visit up to 5 years after SBRT
Freedom from biochemical failure
Time Frame: 5 years after SBRT

Time from SBRT to biochemical failure, defined by the Phoenix criteria (PSA nadir + 2 ng/mL), estimated by the Kaplan-Meier method.

5 years after SBRT
Local recurrence-free survival
Time Frame: 5 years after SBRT

Time from SBRT to recurrence within the prostate, estimated by the Kaplan-Meier method.

5 years after SBRT
Overall survival
Time Frame: 5 years after SBRT

Time from SBRT to death from any cause, estimated by the Kaplan-Meier method.

5 years after SBRT
Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY)
Time Frame: 5 years after SBRT

Cost and utility data will be used to evaluate cost-effectiveness by calculating the incremental cost-effectiveness ratio (ICER). Uncertainty analyses will be performed using one-way sensitivity analysis, probabilistic sensitivity analysis, and threshold analysis.

5 years after SBRT

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 2, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2033

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 15, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 15, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared outside the study team. The informed consent and ethics approval do not cover data sharing.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe